Risk Factors for Sinusoidal Obstruction Syndrome After Hematopoietic Stem Cell Transplantation in Children and Young Adults: A Systematic Review and Meta-Analysis

IF 1.9 4区医学 Q2 SURGERY

Clinical Transplantation Pub Date : 2024-09-11 DOI:10.1111/ctr.15449

Kai Cui, Jie Chen, Senlin Zhang, ChenChen He, Shan Sun, Jie Li

{"title":"Risk Factors for Sinusoidal Obstruction Syndrome After Hematopoietic Stem Cell Transplantation in Children and Young Adults: A Systematic Review and Meta-Analysis","authors":"Kai Cui, Jie Chen, Senlin Zhang, ChenChen He, Shan Sun, Jie Li","doi":"10.1111/ctr.15449","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective and Background</h3>\n \n <p>Sinusoidal obstruction syndrome (SOS) is a life-threatening complication in hematopoietic stem cell transplantation (HSCT) patients. However, the related risk factors in pediatric and young adult HSCT recipients remain unclear. Thus, we conducted this meta-analysis to identify potential risk factors for SOS in children and young adults undergoing HSCT.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>We acquired related articles through searching PubMed, EMBASE, and the Cochrane Library up to May 31, 2024. We calculated odds ratios (ORs) and corresponding 95% confidence intervals (CIs) to identify potential risk factors.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 12 studies with 7644 HSCT recipients were included. Bone marrow transplantation (OR = 1.35, 95% CI: 1.03–1.77, <i>I</i><sup>2</sup> = 0%), busulfan (BU) (OR = 3.63, 95% CI: 1.78–7.38, <i>I</i><sup>2</sup> = 70%), and fludarabine (FLU) (OR = 1.55, 95% CI: 1.09–2.21, <i>I</i><sup>2</sup> = 16%) were risk factors for SOS after HSCT in children and young adults.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Bone marrow transplantation and the use of BU or FLU might be risk factors for SOS after HSCT in children and young adults.</p>\n </section>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.15449","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective and Background

Sinusoidal obstruction syndrome (SOS) is a life-threatening complication in hematopoietic stem cell transplantation (HSCT) patients. However, the related risk factors in pediatric and young adult HSCT recipients remain unclear. Thus, we conducted this meta-analysis to identify potential risk factors for SOS in children and young adults undergoing HSCT.

Method

We acquired related articles through searching PubMed, EMBASE, and the Cochrane Library up to May 31, 2024. We calculated odds ratios (ORs) and corresponding 95% confidence intervals (CIs) to identify potential risk factors.

Results

A total of 12 studies with 7644 HSCT recipients were included. Bone marrow transplantation (OR = 1.35, 95% CI: 1.03–1.77, I² = 0%), busulfan (BU) (OR = 3.63, 95% CI: 1.78–7.38, I² = 70%), and fludarabine (FLU) (OR = 1.55, 95% CI: 1.09–2.21, I² = 16%) were risk factors for SOS after HSCT in children and young adults.

Conclusion

Bone marrow transplantation and the use of BU or FLU might be risk factors for SOS after HSCT in children and young adults.

查看原文本刊更多论文

儿童和青少年造血干细胞移植后窦性阻塞综合征的风险因素：系统回顾和元分析

目的与背景窦性阻塞综合征（SOS）是造血干细胞移植（HSCT）患者的一种危及生命的并发症。然而，儿童和年轻成人造血干细胞移植受者的相关风险因素仍不清楚。因此，我们进行了这项荟萃分析，以确定接受造血干细胞移植的儿童和年轻成人发生SOS的潜在风险因素。方法我们通过搜索 PubMed、EMBASE 和 Cochrane 图书馆获得了截至 2024 年 5 月 31 日的相关文章。我们计算了几率比（OR）和相应的 95% 置信区间（CI），以确定潜在的风险因素。结果共纳入了12项研究，涉及7644名造血干细胞移植受者。骨髓移植（OR = 1.35，95% CI：1.03-1.77，I2 = 0%）、丁硫（BU）（OR = 3.63，95% CI：1.78-7.38，I2 = 70%）和氟达拉滨（FLU）（OR = 1.55，95% CI：1.09-2.21，I2 = 16%）是儿童和年轻人造血干细胞移植后出现 SOS 的风险因素。结论骨髓移植和使用 BU 或 FLU 可能是儿童和青少年造血干细胞移植后出现 SOS 的风险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Transplantation 医学-外科

CiteScore

3.70

自引率

4.80%

发文量

286

审稿时长

2 months

期刊介绍： Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored. Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include: Immunology and immunosuppression; Patient preparation; Social, ethical, and psychological issues; Complications, short- and long-term results; Artificial organs; Donation and preservation of organ and tissue; Translational studies; Advances in tissue typing; Updates on transplant pathology;. Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries. Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.